Latest Pneumococcal conjugate vaccine Stories

The U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously yesterday to recommend that adults ages 19 to 64 with asthma receive pneumococcal polysaccharide vaccine (PPSV23), known as PNEUMOVAX(R) 23 (Pneumococcal Vaccine Polyvalent). Merck & Co., Inc. is the sole supplier of PNEUMOVAX 23 in the United States. The ACIP based this recommendation on study data that showed an increased risk of pneumococcal disease among people...

Britain's All-Party Parliamentary Group on Pneumococcal Disease Prevention officials say pneumococcal disease must be recognized as a global health issue. Between 700,000 and 1 million children under the age 5 die each year from pneumococcal disease and these child deaths are a largely preventable tragedy, the group says. A vaccine against pneumococcal disease exists and is being used in the Britain. The impact of this vaccine has been seen in England and Wales where there has been a 59...

Significant Step in Merck's Efforts to Expand Global Access to Rotavirus Vaccine Media: Nalini Saligram, 215-652-9232 Amy Rose, 908-423-6537 OR Investors: Eva Boratto, 908-423-5185 ROTATEQ(R) (rotavirus vaccine, live, oral, pentavalent), the pentavalent rotavirus vaccine from Merck & Co., Inc., that helps prevent rotavirus gastroenteritis in infants and children, has been awarded pre-qualification status by the World Health Organization (WHO). WHO pre-qualification allows for expanded...

Wyeth Pharmaceuticals, a division of Wyeth, has initiated the community acquired pneumonia immunization trial in adults, a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia. The results from this trial are not intended or required for inclusion in Wyeth's currently planned regulatory filings for the use of the 13-valent pneumococcal conjugate candidate vaccine in adults. Rather, this study is being initiated proactively as...

U.S. scientists say the discovery of a new mechanism of immunity suggests a more effective pneumococcal vaccine might be in the offing. Children's Hospital Boston and Harvard School of Public Health researchers say there might be a better way to protect people against Streptococcus pneumoniae infection. They said the current vaccine, Prevnar, is expensive and covers only 7 of the 91 known pneumococcal strains. Dr. Richard Malley and medical researcher Marc Lipsitch discovered that, in...

Greg MacMichael, Ph.D. has joined Cook Pharmica, the global biopharmaceutical contract development and manufacturing division of Cook Medical, as vice president of development and chief scientific officer. With 25 years of biopharmaceutical experience, MacMichael has worked with a variety of notable companies including Eli Lilly, Chiron and Centocor. Most recently MacMichael served as vice president of Vaccine Development at Wyeth, where he was instrumental in the development of Prevnar,...

COLLEGEVILLE, Pa., Sept. 23 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia -- the leading cause of bacterial pneumonia in adults. In Europe and the United States, pneumococcal pneumonia is the most common community-acquired bacterial pneumonia, for which the...

Reportlinker.com announces that a new market research report related to the Infectious diseases industry is available in its catalogue. World Human Vaccines Market http://www.reportlinker.com/p092575/World-Human-Vaccines-Market.html This report analyzes the worldwide markets for Human Vaccines in Millions of US$. The major product segments analyzed are Prophylactic Vaccines (Pediatric Prophylactic Vaccines, & Adult Prophylactic Vaccines), and Therapeutic Vaccines. The report provides...

COLLEGEVILLE, Pa., Sept. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced that South Africa has initiated an immunization program against pneumococcal disease with PREVENAR(R) (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed), a vaccine which helps protect infants and young children against the seven vaccine serotypes causing the majority of pneumococcal disease worldwide. The South African government launched the pneumococcal disease...

MAIDENHEAD, England, September 4 /PRNewswire-FirstCall/ -- - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide Wyeth today announced that Cyprus and the Republic of Ireland have initiated national immunisation programmes (NIPs) for infants and young children against pneumococcal disease by adding Prevenar(TM) (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed), also called PCV7, to their national immunization...